Author: Dr. David Lowemann

New Drug Preserves Muscle in Wegovy Patients

Veru said on Monday its experimental drug, in combination with Novo Nordisk’s weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage study. The study was testing Veru’s oral drug, enobosarm, in patients aged… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is […]

Published on January 27, 2025

Adderall Shortage Sparks Scramble for Alternatives

Adderall shortages have prompted doctors to switch kids with attention-deficit/hyperactivity disorder (ADHD) to other forms of stimulant medication. Adderall prescription fills for children and teens plunged after the U.S. Food and Drug Administration (FDA) announced a… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for […]

Published on January 27, 2025

FDA OKs Monthly Maintenance Dose for Leqembi

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan’s Eisai and partner Biogen’s Alzheimer’s drug Leqembi, the companies said on Monday. The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a […]

Published on January 27, 2025